HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 282, Issue 46, 33817-33830, November 16, 2007

This Article Full Text Full Text (PDF) All Versions of this Article: 282/46/33817    most recent M700195200v1 Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Benziane, B. Articles by Laghmani, K. Search for Related Content PubMed PubMed Citation Articles by Benziane, B. Articles by Laghmani, K. Social Bookmarking                      What's this?

NKCC2 Surface Expression in Mammalian Cells

DOWN-REGULATION BY NOVEL INTERACTION WITH ALDOLASE B^*

Boubacar Benziane, Sylvie Demaretz, Nadia Defontaine, Nancy Zaarour, Lydie Cheval^¶, Soline Bourgeois, Christophe Klein, Marc Froissart^||, Anne Blanchard^||, Michel Paillard^||, Gerardo Gamba^**, Pascal Houillier^||, and Kamel Laghmani¹

From the INSERM U652, 75006 Paris, France, ^¶CNRS-UPMC UMR7134, 75006 Paris, France, IFR58, Institut des Cordeliers, 75006 Paris, France, Universite Paris-Descartes, 75006 Paris, France, ^**Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran and Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico, Tlalpan, Mexico City 14000, Mexico, and ^||AP-HP, Departement de Physiologie, Hopital Europeen Georges Pompidou, 75015 Paris, France

Apical bumetanide-sensitive Na⁺-K⁺-2Cl^- co-transporter, termed NKCC2, is the major salt transport pathway in kidney thick ascending limb. NKCC2 surface expression is subject to regulation by intracellular protein trafficking. However, the protein partners involved in the intracellular trafficking of NKCC2 remain unknown. Moreover, studies aimed at under-standing the post-translational regulation of NKCC2 have been hampered by the difficulty to express NKCC2 protein in mammalian cells. Here we were able to express NKCC2 protein in renal epithelial cells by tagging its N-terminal domain. To gain insights into the regulation of NKCC2 trafficking, we screened for interaction partners of NKCC2 with the yeast two-hybrid system, using the C-terminal tail of NKCC2 as bait. Aldolase B was identified as a dominant and novel interacting protein. Real time PCR on renal microdissected tubules demonstrated the expression of aldolase B in the thick ascending limb. Co-immunoprecipitation and co-immunolocalization experiments confirmed NKCC2-aldolase interaction in renal cells. Biotinylation assays showed that aldolase co-expression reduces NKCC2 surface expression. In the presence of aldolase substrate, fructose 1,6-bisphosphate, aldolase binding was disrupted, and aldolase co-expression had no further effect on the cell surface level of NKCC2. Finally, functional studies demonstrated that aldolase-induced down-regulation of NKCC2 at the plasma membrane was associated with a decrease in its transport activity. In summary, we identified aldolase B as a novel NKCC2 binding partner that plays a key role in the modulation of NKCC2 surface expression, thereby revealing a new regulatory mechanism governing the co-transporter intracellular trafficking. Furthermore, NKCC2 protein expression in mammalian cells and its regulation by protein-protein interactions, described here, may open new and important avenues in studying the cell biology and post-transcriptional regulation of the co-transporter.

Received for publication, January 8, 2007 , and in revised form, August 17, 2007.

^* This work was supported by grants from INSERM, Paris, France. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement"in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ To whom correspondence should be addressed: INSERM U652, 15 Rue de l'Ecole de Medecine, 75270 Paris Cedex 06, France. Tel.: 33-1-44-41-37-10; Fax: 33-1-44-41-37-17; E-mail: Kamel.Laghmani{at}bhdc.jussieu.fr.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?